Drug Profile
Pembrolizumab biosimilar - mAbxience Research
Alternative Names: MB-12Latest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator mAbxience
- Developer Laboratorios Phoenix; mAbxience
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Non-small cell lung cancer
Most Recent Events
- 15 Aug 2023 Phase-III clinical trials in Non-small cell lung cancer (Metastatic disease, First-line therapy, Late-stage disease) in Chile (IV) (NCT05668650)
- 30 Dec 2022 mAbxience plans a phase III trial for Non small cell lung cancer (Metastatics diseases, Late stage diaseases, In elderly, In adults) (IV) in March 2023 (NCT05668650)
- 30 Dec 2022 Clinical trials in Non-small cell lung cancer (Parenteral) (mAbxience Research pipeline, December 2022)